ASX:MSBBiotechs
Mesoblast (ASX:MSB) Is Up 17.3% After Lifting Revenue Guidance and Announcing NIH Trial Collaboration Has The Bull Case Changed?
Mesoblast Limited recently released updated revenue guidance, projecting gross revenue of over US$30.0 million from Ryoncil® sales for the quarter ending December 31, 2025, and announced a collaborative pivotal trial with the NIH-funded Blood and Marrow Transplant Clinical Trials Network for Ryoncil® in adults with severe acute graft versus host disease.
This combination of higher sales forecasts and expanded clinical research signals an important step as Mesoblast seeks to broaden both its...